Theriva Biologics, Inc. Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs
Theriva Biologics, Inc. (TOVX) had Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs of $5.25 million as of 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities
us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts · last filed 2026-03-12
- 2025-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $5.25M.
- 2024-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $4.34M.
- 2023-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $4.94M.
- 2022-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $4.79M.
| Period end | Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs |
|---|---|
| 2025-12-31 | $5.25M 10-K · filed 2026-03-12 |
| 2024-12-31 | $4.34M 10-K · filed 2026-03-12 |
| 2023-12-31 | $4.94M 10-K · filed 2025-03-06 |
| 2022-12-31 | $4.79M 10-K · filed 2024-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |